CD274 and neoplasm: In this disease model, Siglec-15 functions as a “ligand” for an unknown inhibitory receptor on cytotoxic T cells, where it acts in a similar manner as PD-L1 (B7-H1, CD274) on tumor cells or tumor stroma involving immune checkpoint molecule PD-1 on T cells [14,20].